PTCNASDAQ: PTC

On Wednesday, PTC Therapeutics announced that the U.S. Food and Drug Administration has approved their gene therapy, which is given directly into the brain. This treatment is designed for a serious enzyme deficiency disorder that could be life-threatening.

PTC Therapeutics, Inc. has received accelerated approval from the FDA for its gene therapy aimed at treating AADC deficiency, marking the first gene therapy in the U.S. that is delivered directly to the brain. The therapy has been granted a priority review voucher and is approved for use in both children and adults. This innovative approach by PTC is a significant advancement in drug delivery for central nervous system conditions.

PTC's performance in the fourth quarter is supported by consistent growth in recurring revenues, even in a challenging sales environment.

On Wednesday, PTC, a company that creates industrial software, predicted that its revenue for the first quarter would be lower than expected. This suggests that there is still weak demand for its design and testing software, as businesses are being careful with their spending.

WARREN, N.J., Nov. 4, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that it will give a company overview at upcoming conferences, including the UBS Global Healthcare Conference on Wednesday, Nov. 13 at 2:45 p.m.

Assess the anticipated performance of PTC Inc. (PTC) for the quarter that ended in September 2024. Instead of just focusing on the usual revenue and profit predictions from Wall Street, let's take a closer look at some important metrics for a deeper understanding.

PTC Inc. (PTC) lacks the necessary elements that could lead to a strong earnings report in the near future. Be ready for the main expectations.

Self-protecting devices are designed to handle energy levels of up to 340 J, with resistance values of 1.5 kΩ and can operate at high voltages of 1200 VDC. These devices help to reduce the number of components needed in a system. This combination enhances efficiency and safety in electrical applications.

WARREN, N.J., Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that the U.S. Food and Drug Administration (FDA) will review the resubmitted New Drug Application (NDA) for Translarna™ (ataluren), which is intended to treat nonsense mutation Duchenne muscular dystrophy (nmDMD).